Bladder cancer continues to challenge oncologists worldwide, particularly in its advanced, recurrent, and treatment-resistant forms. Despite progress in surgical techniques, chemotherapeutic regimens, and targeted molecular therapies, durable responses remain elusive for many patients. In this context, a groundbreaking study illuminates a novel vulnerability within bladder cancer cells by delineating the interplay between autophagy—a fundamental cellular recycling mechanism—and ferroptosis, a distinct iron-dependent programmed cell death pathway. The investigative team reveals that JS-K, a nitric oxide (NO)-releasing prodrug, drives bladder cancer cells into ferroptosis by orchestrating mitochondrial dysfunction, perturbations in iron homeostasis, and heightened oxidative stress while concurrently dismantling key cellular survival pathways.
Ferroptosis has emerged as a captivating mode of cell death owing to its reliance on iron-mediated lipid peroxidation and reactive oxygen species (ROS), setting it apart mechanistically from apoptosis or necrosis. Yet, the crosstalk between autophagy—especially LC3B-mediated autophagic flux—and ferroptosis in bladder cancer remains inadequately explored. This study leverages a comprehensive multimodal approach integrating cellular assays, murine xenograft models, and transcriptomics, including single-cell RNA sequencing, to unravel the molecular underpinnings by which JS-K exploits this axis to suppress tumor progression.
Cell culture experiments employing human bladder cancer lines T24 and UM-UC-3 unveiled classical hallmarks of ferroptosis upon JS-K administration. These included distinctive mitochondrial shrinkage observed via electron microscopy, excessive lipid peroxidation evidenced by malondialdehyde accumulation, an overwhelming surge in intracellular ROS, and iron overload. Concomitantly, pivotal ferroptosis safeguard proteins glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11 or xCT) were markedly downregulated, signifying a collapse of cellular antioxidative defenses.
Crucially, impairment or genetic silencing of LC3B—a core autophagy protein—dampened JS-K’s ability to induce iron build-up, oxidative damage, and consequent cell death. This elegant finding positions autophagy upstream as a facilitator rather than merely a bystander of ferroptosis in this context. The data imply that autophagic processes may selectively degrade ferritin or other iron storage complexes, incrementally raising free iron levels that catalyze lipid peroxidation and ferroptotic demise.
Extending these observations in vivo, JS-K administered to immunodeficient BALB/c nude mice bearing human bladder cancer xenografts produced significant tumor growth inhibition. Importantly, mice harboring tumors with silenced LC3B expression exhibited an attenuated therapeutic response, corroborating the mechanistic necessity of autophagy for optimal ferroptosis induction and antitumor efficacy. Histopathological assessment further confirmed altered protein expression patterns consistent with ferroptotic cell death pathways.
Interrogation of bulk and single-cell RNA-sequencing datasets from treated tumor tissues illuminated co-expression networks linking LC3B with ferroptosis-associated genes including CISD1 and nuclear receptor coactivator 4 (NCOA4). Among these, CISD1 emerged as a prognostically relevant biomarker, inversely correlating with clinical outcomes and highlighting its potential utility in stratifying patients for autophagy–ferroptosis-targeted therapies.
At the cellular level, JS-K’s release of nitric oxide initiates mitochondrial impairment by disrupting electron transport chain components, thereby exacerbating ROS generation. This metabolic insult, compounded by impaired iron metabolism, destabilizes the delicate redox equilibrium within cancer cells. The consequential depletion of GPX4 and xCT disables glutathione-dependent antioxidant systems, enabling unchecked lipid peroxide accumulation that culminates in ferroptotic death.
This research reframes the traditional view of autophagy and ferroptosis as independent processes, revealing a synergistic relationship that can be leveraged therapeutically. The dual impact of JS-K on cancer cell metabolism and survival pathways not only enhances ferroptosis but also impairs the autophagic recycling that would otherwise mitigate cellular damage—a double hit exploiting tumor vulnerabilities.
From a translational perspective, these findings offer a blueprint for the rational development of ferroptosis-based therapeutics in bladder cancer, a malignancy with few effective options beyond frontline chemotherapy. The identification of LC3B as both a mechanistic driver and biomarker enables potential patient stratification, potentially guiding personalized interventions where JS-K or similar agents might yield maximal efficacy.
Beyond direct tumor cell killing, modulation of the autophagy–ferroptosis interface may also influence the tumor immune microenvironment. Preliminary transcriptomic insights suggest that alterations in ferroptotic signaling could reshape immune cell infiltration and activation, opening avenues for combinatorial strategies incorporating immunotherapy.
Although JS-K remains at the experimental stage, its multifaceted mechanism—combining oxidative stress amplification, disruption of iron homeostasis, and suppression of antioxidant defenses—presents a compelling case for further pharmacokinetic and toxicological evaluations. Such efforts will be critical to clarify safety, dosing parameters, and therapeutic windows, paving the way for early-phase clinical trials.
Ultimately, this study propels the field toward new horizons where inducing autophagy-dependent ferroptosis could overcome resistance mechanisms that stymie conventional treatments. By illuminating this previously underappreciated axis in bladder cancer biology, the work not only offers hope for improved outcomes but also enriches the conceptual framework for future cancer drug discovery.
As the oncology community continues to grapple with lethal and refractory tumors, innovations such as JS-K-induced ferroptosis represent a paradigm shift. They underscore the necessity of targeting fundamental metabolic and survival processes, exploiting the intrinsic liabilities of cancer cells, and embracing integrated multimodal research strategies that bridge bench to bedside.
Subject of Research:
Not applicable
Article Title:
JS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study
News Publication Date:
25-Apr-2026
References:
DOI: 10.1093/pcmedi/pbag012
Image Credits:
Precision Clinical Medicine
Keywords:
Bladder cancer, ferroptosis, autophagy, JS-K, nitric oxide prodrug, iron metabolism, oxidative stress, LC3B, GPX4, xCT, tumor microenvironment, targeted therapy
